Similarly, elevated dNLR (>3) demonstrated significant correlations with inferior PFS and OS (both P < 0.05) in patients with advanced NSCLC expressing at least 50% PD-L1 on tumor cells and treated with first-line Pembrolizumab (74). The gene discussed is CD274; the disease is non-small cell lung carcinoma.